CoChat
Sign Up
Cited by 2Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsCholesterol and Lipid Metabolism

Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors

Open access
Karahan, Hande, Hartigan, Kelly, Al‐Amin, Md Mamun, John, Sutha K., McCord, Brianne, Wijeratne, H. R. Sagara, Acri, Dominic J., Smith, Daniel C. +5 more·2025·Alzheimer's & Dementia
DOI 10.1002/alz.70949PMC PMC12699379
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Overexpression of the low‐density lipoprotein receptor (LDLR) is known to decrease apolipoprotein E (APOE) levels and alleviate amyloid beta (Aβ) pathology. We hypothesized that inhibiting the Inducible Degrader of LDLR (IDOL), an enzyme that ubiquitinates LDLR for degradation, would increase endogenous LDLR levels and attenuate amyloid pathology. METHODS: To investigate the cell‐type–specific role of IDOL, we generated Idol conditional knockout mice on an Aβ‐amyloidosis mouse model and performed biochemical, histological, and multi‐omics analyses. RESULTS: We demonstrated that neuronal, but not microglial, Idol deletion reduced amyloid accumulation and altered brain LDLR and APOE levels, indicating the critical role of neuronal IDOL‐LDLR in amyloid pathology. In addition, neuronal Idol deletion increased the levels of Reelin receptors important for synaptic function, and single‐nuclei RNA sequencing revealed significant changes associated with synaptic organization. DISCUSSION: Neuronal IDOL, but not microglial IDOL, plays a key role in Alzheimer's disease pathogenesis by regulating the levels of brain APOE receptors. Highlights: Neuronal, but not microglial, Idol deletion reduces amyloid burden and modulates brain APOE and LDLR levels. Deletion of neuronal Idol increases the levels of APOER2 and VLDLR, the Reelin receptors, in the brain. Single‐nuclei RNA sequencing highlights the neuronal IDOL's impact on inhibitory neurons and synaptic organization. Targeting neuronal IDOL may provide multiple therapeutic benefits in Alzheimer's disease by modulating APOE receptors.

Verification finished with gaps

Some checks didn’t finish. The results below cover the steps that did.

  1. Registry recordVerified
  2. Full textRead the full text
  3. Reference list52 references found
  4. Reference check86 of 86 references checked
  5. StatisticsRecomputed
  6. Claims179 claims anchored to a quote
  7. Cited sourcesChecked
  8. Self-checkDidn’t finish — the rest of the report still applies.
  9. VerificationFindings verified

AI snapshot

Written from the paper’s full text.

TL;DR

Neuronal, but not microglial, deletion of the E3 ubiquitin ligase Idol in 5XFAD mice reduced amyloid beta accumulation and gliosis while increasing brain LDLR and Reelin receptors and decreasing APOE. The authors conclude that neuronal IDOL regulates AD-related pathology through APOE receptors and may be a therapeutic target.

Key findings

  • Neuronal Idol deletion reduced cortical insoluble Aβ40 and Aβ42 by 69% and 61%, respectively, and soluble Aβ40/Aβ42 by 34% and 45%; hippocampal insoluble Aβ40/Aβ42 decreased by 30% and 25%. Microglial Idol deletion did not change cortical insoluble Aβ40 or Aβ42.
  • Neuronal Idol deletion increased LDLR and decreased APOE in brain, whereas microglial Idol deletion changed neither; it also increased APOER2 and VLDLR, the Reelin receptors.
  • Proteomics detected 11,829 proteins and highlighted lipid metabolism/cholesterol transport, with “Cholesterol dysregulation in Alzheimer's disease” as the top pathway.
  • snRNA-seq found reduced proportions of inhibitory neuron clusters 10 and 22, identified as Meis2+ neurons, and CellChat showed increased neuronal signaling, especially involving inhibitory/excitatory neurons and neurexin/GABA-A/glutamate pathways.

Methods

  • Generated microglia-specific (5XFAD;MG cKO) and neuron-specific (5XFAD;Neu cKO) Idol conditional knockout mice on the 5XFAD Aβ-amyloidosis model; microglial deletion was tamoxifen-inducible at 1.5 months, and brains were collected at 4 months. Female mice were used in all experiments.
  • Measured Aβ by electrochemiluminescence, proteins by Western blot, plaques/gliosis by immunohistochemistry, and performed proteomics, bulk RNA-seq, and single-nuclei RNA-seq with pathway/network analyses.
  • Statistical comparisons used unpaired two-tailed t-tests with p < 0.05 considered significant; sample sizes were based on power calculations, and histology quantification was blinded.

Limitations

  • Stated: snRNA-seq used a modest sample size (N = 2 mice/genotype), and larger sample sizes are required to capture transcriptomic alterations and biological variability.
  • Stated: the study did not assess tauopathy, and future research should determine whether neuronal IDOL inhibition can therapeutically alter AD pathologies and cognitive outcomes.
  • Evident from the text: all experiments used female mice only, at a single 4-month time point, in the 5XFAD mouse model, with no human validation reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/alz.70949

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

68 of 99 cited sources checked · 46 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    APOE binds to cell surface receptors including LDLR, LRP1, VLDLR, and APOER2.

    “APOE binds to cell surface receptors, such as low‐density lipoprotein receptor (LDLR), LDLR‐related protein 1 (LRP1), very low‐density lipoprotein receptor (VLDLR), and apolipoprotein E receptor 2 (APOER2 or LRP8). 2 , 14 , 15”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [2] Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022; 17(1): 72. doi: 10.1186/s13024-022-00574-4 36348357 PMC9644639 source

      The “APOE biology: synthesis, structure, and function” section says apoE binds cell-surface receptors including LDLR and LRP1. The passages found do not identify VLDLR or APOER2 (LRP8) as apoE-binding receptors; the paper’s mention of VLDL refers to a lipoprotein, not its receptor. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [14] Lane‐Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer's disease. Trends Endocrinol Metab. 2017; 28(4): 273‐ 284. doi: 10.1016/j.tem.2016.12.001 28057414 PMC5366078 source
    • cites [15] Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron. 2014; 81(4): 740‐ 754. doi: 10.1016/j.neuron.2014.01.045 24559670 PMC3983361 source
  • Premisecitation

    Overexpression of Ldlr decreases both APOE and Aβ levels by enhancing Aβ clearance in amyloidosis mouse models.

    “Indeed, overexpression of Ldlr decreased both APOE and Aβ levels by enhancing Aβ clearance in amyloidosis mouse models. 16 , 18”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [16] Kim J, Castellano JM, Jiang H, et al. Overexpression of low‐density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009; 64(5): 632‐ 644. doi: 10.1016/j.neuron.2009.11.013 20005821 PMC2787195 source
    • cites [18] Castellano JM, Deane R, Gottesdiener AJ, et al. Low‐density lipoprotein receptor overexpression enhances the rate of brain‐to‐blood Aβ clearance in a mouse model of β‐amyloidosis. Proc Natl Acad Sci USA. 2012; 109(38): 15502‐ 15507. doi: 10.1073/pnas.1206446109 22927427 PMC3458349 source
  • Premisecitation

    IDOL is an E3 ubiquitin ligase that ubiquitinates LDLR, triggering its lysosomal degradation.

    “IDOL is an E3 ubiquitin ligase that ubiquitinates LDLR, thereby triggering its lysosomal degradation. 19”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [19] Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol‐dependent ubiquitination of the LDL receptor. Science. 2009; 325(5936): 100‐ 104. doi: 10.1126/science.1168974 19520913 PMC2777523 source
  • Premisecitation

    APOE influences Alzheimer's disease-related pathologies including Aβ accumulation, tauopathy, neuroinflammation, and synaptic impairment.

    “These efforts have resulted in identifying multiple mechanisms by which APOE influences AD‐related pathologies, including amyloid beta (Aβ) accumulation, tauopathy, neuroinflammation, and synaptic impairment. 2”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [2] Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022; 17(1): 72. doi: 10.1186/s13024-022-00574-4 36348357 PMC9644639 source
  • Premisecitation

    Female mice exhibit more pronounced amyloid pathology in the 5XFAD model.

    “Female mice were used in all experiments, as females exhibit more pronounced amyloid pathology in the 5XFAD model. 21”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [21] Oakley H, Cole SL, Logan S, et al. Intraneuronal beta‐amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26(40): 10129‐ 10140. doi: 10.1523/JNEUROSCI.1202-06.2006 17021169 PMC6674618 source

      In “5XFAD mice rapidly accumulate massive Aβ42 levels in brain” (page unavailable), the authors report that young female mice in two 5XFAD lines tended to have slightly higher cerebral Aβ42 levels than age-matched males. They say the trend diminished at older ages and do not establish that females generally have more pronounced amyloid pathology or greater plaque burden. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim. 35
  • May combine two claims. 43

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    APOE genotype remains the strongest known risk factor for late-onset Alzheimer's disease.

    “However, apolipoprotein E (APOE) genotype remains the strongest known risk factor. 1”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [1] Serrano‐Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021; 20(1): 68‐ 80. doi: 10.1016/s1474-4422(20)30412-9 33340485 PMC8096522 source

      The Introduction calls the APOE ε4 allele the strongest genetic risk factor for sporadic Alzheimer’s disease. The citing sentence omits “genetic,” so the source does not support calling APOE genotype the strongest known risk factor overall. No page number is available in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    APOE is mainly secreted by astrocytes but is also expressed in microglia, neurons, and oligodendrocytes, particularly under injury and degenerative conditions.

    “Although mainly secreted by astrocytes, APOE is also expressed in microglia, neurons, and oligodendrocytes, particularly under injury and degenerative conditions. 2 , 13”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [2] Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022; 17(1): 72. doi: 10.1186/s13024-022-00574-4 36348357 PMC9644639 source

      The Physiological function of apoE section says apoE expression rises in activated microglia and stressed neurons under pathological conditions and injury, and that oligodendrocytes express it more abundantly after injury. It also says astrocytes express and secrete apoE, but does not establish that astrocytes are its main source of secretion. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [13] Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of Apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006; 26(19): 4985‐ 4994. doi: 10.1523/jneurosci.5476-05.2006 16687490 PMC6674234 source

  • May combine two claims.

    Premisecitation

    Genetic deletion and pharmacological reduction of APOE reduce Aβ deposition in mouse models of Alzheimer's disease.

    “Both genetic deletion and pharmacological reduction of APOE reduced Aβ deposition in mouse models of AD. 3 , 4 , 5 , 6 , 7 , 8 , 9”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites [3] Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta‐peptide deposition. Nat Genet. 1997; 17(3): 263‐ 264. doi: 10.1038/ng1197-263 9354781 source
    • cites [4] Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999; 96(26): 15233‐ 15238. doi: 10.1073/pnas.96.26.15233 10611368 PMC24803 source
    • cites [5] Kim J, Jiang H, Park S, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid‐beta amyloidosis. J Neurosci. 2011; 31(49): 18007‐ 18012. doi: 10.1523/JNEUROSCI.3773-11.2011 22159114 PMC3257514 source

      The Discussion reports that mice with one human APOE copy had significantly less Aβ accumulation and amyloid deposition than mice with two copies, supporting the genetic-reduction part of the claim. It describes pharmacological approaches as having produced conflicting results; it does not establish that pharmacological reduction of APOE reduced deposition. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Prior work using conventional global Idol knockout demonstrated that Idol deletion increases endogenous LDLR levels, coinciding with reduced amyloid plaque burden and neuroinflammation in an Aβ-amyloidosis mouse model.

    “Our prior work using a conventional global Idol knockout (KO) model demonstrated that Idol deletion was sufficient to increase endogenous LDLR levels, coinciding with reduced amyloid plaque burden and neuroinflammation in an Aβ‐amyloidosis mouse model. 20”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [20] Choi J, Gao J, Kim J, Hong C, Kim J, Tontonoz P. The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis. Sci Transl Med. 2015; 7(314): 314ra184. doi: 10.1126/scitranslmed.aad1904 PMC7153735 26582899 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Ldlr overexpression markedly reduces amyloid plaque deposition.

    “For example, Ldlr overexpression markedly reduces amyloid plaque deposition. 16”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [16] Kim J, Castellano JM, Jiang H, et al. Overexpression of low‐density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009; 64(5): 632‐ 644. doi: 10.1016/j.neuron.2009.11.013 20005821 PMC2787195 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    APOE primarily mediates lipid transport in the brain.

    “The APOE protein primarily mediates lipid transport in the brain. 12”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [12] Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol. 2017; 28(1): 60‐ 67. doi: 10.1097/mol.0000000000000383 27922847 PMC5213812 source

  • May combine two claims.

    Premisecitation

    Overexpression of LDLR decreases APOE levels and alleviates amyloid beta (Aβ) pathology.

    “Overexpression of the low‐density lipoprotein receptor (LDLR) is known to decrease apolipoprotein E (APOE) levels and alleviate amyloid beta (Aβ) pathology.”
    • Also stated in: § BACKGROUND · plain
      “For example, Ldlr overexpression markedly reduces amyloid plaque deposition. 16”
    • Also stated in: § BACKGROUND · plain
      “Indeed, overexpression of Ldlr decreased both APOE and Aβ levels by enhancing Aβ clearance in amyloidosis mouse models. 16 , 18”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [16] Kim J, Castellano JM, Jiang H, et al. Overexpression of low‐density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009; 64(5): 632‐ 644. doi: 10.1016/j.neuron.2009.11.013 20005821 PMC2787195 source
    • cites [18] Castellano JM, Deane R, Gottesdiener AJ, et al. Low‐density lipoprotein receptor overexpression enhances the rate of brain‐to‐blood Aβ clearance in a mouse model of β‐amyloidosis. Proc Natl Acad Sci USA. 2012; 109(38): 15502‐ 15507. doi: 10.1073/pnas.1206446109 22927427 PMC3458349 source

  • May combine two claims.

    Premisecitation

    Idol is expressed ubiquitously, with the highest expression in microglia and neurons in the brain.

    “Idol is expressed ubiquitously, with the highest expression in microglia and neurons in the brain. 20 , 49”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [20] Choi J, Gao J, Kim J, Hong C, Kim J, Tontonoz P. The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis. Sci Transl Med. 2015; 7(314): 314ra184. doi: 10.1126/scitranslmed.aad1904 PMC7153735 26582899 source

      The Results section on the LXR-Idol pathway reports Idol mRNA in all examined mouse CNS subregions, with abundant expression in microglia and neurons and lower expression in astrocytes. This supports the brain-cell comparison, but not an unqualified claim that Idol is expressed ubiquitously beyond the examined CNS regions. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [49] Gao J, Marosi M, Choi J, et al. The E3 ubiquitin ligase IDOL regulates synaptic ApoER2 levels and is important for plasticity and learning. eLife. 2017; 6. doi: 10.7554/eLife.29178 PMC5593505 28891791 source

      The Results section (“Dynamic regulation of neuronal ApoER2 expression by IDOL”; page unavailable) reports that IDOL was widely and highly expressed in neurons. It does not establish ubiquitous expression or say that expression is highest in microglia and neurons; searches for microglia and ubiquitous expression found no supporting passage. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    LDLR is one of the major APOE receptors in the brain and facilitates the endocytosis of APOE-bound lipoprotein particles.

    “LDLR is one of the major APOE receptors in the brain and facilitates the endocytosis of APOE‐bound lipoprotein particles. 59”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [59] Fryer JD, Demattos RB, McCormick LM, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005; 280(27): 25754‐ 25759. doi: 10.1074/jbc.M502143200 15888448 source

  • May combine two claims.

    Premisecitation

    Cells treated with lipidated-APOE2 exhibit decreased APOE-LDLR binding and reduced uptake of lipidated-APOE compared to APOE3 and APOE4, preventing excessive lipid burden and lysosomal pathology.

    “Cells treated with lipidated‐APOE2 exhibited decreased APOE‐LDLR binding and reduced uptake of lipidated‐APOE, thereby preventing excessive lipid burden and lysosomal pathology compared to APOE3 and APOE4.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [70] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206. e26. doi: 10.1016/j.cell.2024.10.027 39532095 PMC11724755 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    APOE2 is the most efficient at promoting cholesterol efflux, and APOE4 is the least efficient, correlating inversely with AD risk.

    “While APOE2 is the most efficient at promoting cholesterol efflux, APOE4 is the least efficient, correlating inversely with AD risk.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [65] Minagawa H, Gong JS, Jung CG, et al. Mechanism underlying apolipoprotein E (ApoE) isoform‐dependent lipid efflux from neural cells in culture. J Neurosci Res. 2009; 87(11): 2498‐ 2508. doi: 10.1002/jnr.22073 19326444 PMC3065888 source

      The Results report greater cholesterol efflux with ApoE3 than ApoE4 in cultured neural cells, and the introductory passage describes ApoE4 as an AD risk factor. The paper does not establish that ApoE2 is the most efficient or compare efflux across all three isoforms; its proposed connection between cholesterol handling and AD risk is also hedged. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [66] Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform‐specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000; 74(3): 1008‐ 1016. doi: 10.1046/j.1471-4159.2000.0741008.x 10693931 source

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    APOE regulates Aβ clearance via LDL receptors and microglia are critical for Aβ clearance.

    “Since APOE regulates Aβ clearance via LDL receptors and microglia are critical for Aβ clearance, 15 we first focused on the role of IDOL in microglia.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [15] Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron. 2014; 81(4): 740‐ 754. doi: 10.1016/j.neuron.2014.01.045 24559670 PMC3983361 source

  • Classified as probably not a substantial claim.

    Premisecitation

    CellChat infers communication networks between cell groups based on the expression of ligands, receptors, and cofactors.

    “CellChat infers communication networks between cell groups based on the expression of ligands, receptors, and cofactors. 48”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [48] Jin S, Guerrero‐Juarez CF, Zhang L, et al. Inference and analysis of cell‐cell communication using CellChat. Nature Communications. 2021; 12(1): 1088. doi: 10.1038/s41467-021-21246-9 PMC7889871 33597522 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    IDOL induces post-translational modifications by ubiquitinating its substrates.

    “IDOL induces post‐translational modifications by ubiquitinating its substrates, 19 , 53 but neuronal Idol deletion may also result in transcriptomic changes.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [19] Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol‐dependent ubiquitination of the LDL receptor. Science. 2009; 325(5936): 100‐ 104. doi: 10.1126/science.1168974 19520913 PMC2777523 source
    • cites [53] Hong C, Duit S, Jalonen P, et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem. 2010; 285(26): 19720‐ 19726. doi: 10.1074/jbc.M110.123729 20427281 PMC2888382 source

  • May combine two claims.

    Premisecitation

    LDLR plays a critical role in regulating Aβ accumulation and is a potential therapeutic target for AD.

    “These findings underscore the critical role of LDLR in regulating Aβ accumulation and position it as a potential therapeutic target for AD.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [16] Kim J, Castellano JM, Jiang H, et al. Overexpression of low‐density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009; 64(5): 632‐ 644. doi: 10.1016/j.neuron.2009.11.013 20005821 PMC2787195 source
    • cites [18] Castellano JM, Deane R, Gottesdiener AJ, et al. Low‐density lipoprotein receptor overexpression enhances the rate of brain‐to‐blood Aβ clearance in a mouse model of β‐amyloidosis. Proc Natl Acad Sci USA. 2012; 109(38): 15502‐ 15507. doi: 10.1073/pnas.1206446109 22927427 PMC3458349 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Neurexins can bind to Aβ and APP, thereby preventing Aβ-induced synaptic pathology and mediating the synaptogenic activity of APP.

    “In addition, neurexins can bind to Aβ and amyloid precursor protein (APP), thereby preventing Aβ‐induced synaptic pathology and mediating the synaptogenic activity of APP. 56 , 57 , 58”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [56] Cvetkovska V, Ge Y, Xu Q, Li S, Zhang P, Craig AM. Neurexin‐β mediates the synaptogenic activity of amyloid precursor protein. J Neurosci. 2022; 42(48): 8936‐ 8947. doi: 10.1523/jneurosci.0511-21.2022 36261284 PMC9732828 source
    • cites [57] Naito Y, Tanabe Y, Lee AK, Hamel E, Takahashi H. Amyloid‐β oligomers interact with neurexin and diminish neurexin‐mediated excitatory presynaptic organization. Sci Rep. 2017; 7: 42548. doi: 10.1038/srep42548 28211900 PMC5304201 source

      The Discussion reports that neurexins bind Aβ42 oligomers. It says this interaction reduces neurexin expression on axons and may contribute to synaptic pathology; blocking the interaction is proposed as a possible way to prevent pathology. The cited paper does not establish that neurexins bind APP or mediate APP’s synaptogenic activity. No page numbers are available in our copy. (LLM, conf=0.89)

      Experimental — accuracy not yet measured
    • cites [58] Brito‐Moreira J, Lourenco MV, Oliveira MM, et al. Interaction of amyloid‐β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem. 2017; 292(18): 7327‐ 7337. doi: 10.1074/jbc.M116.761189 28283575 PMC5418035 source

      The Discussion (page not provided) reports that Aβ oligomers bind neurexins, but says this interaction may contribute to synapse damage. The paper attributes prevention of Aβ-induced synapse loss to antibodies that block the interaction, not to neurexin binding itself. The passages do not establish neurexin binding to APP or mediation of APP’s synaptogenic activity. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Inhibition of Idol with an antisense oligonucleotide reduces amyloid burden in an APP transgenic mouse model.

    “In addition, the inhibition of Idol with an antisense oligonucleotide was reported to reduce the amyloid burden in an APP transgenic mouse model. 62”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [62] Gao J, Littman R, Diamante G, et al. Therapeutic Idol reduction ameliorates amyloidosis and improves cognitive function in APP/PS1 mice. Mol Cell Biol. 2020; 40(8): e00518‐ 19. doi: 10.1128/mcb.00518-19 31964754 PMC7108818 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    APOE isoforms differ in their ability to regulate lipid metabolism and cholesterol efflux.

    “One key difference among APOE isoforms is their ability to regulate lipid metabolism and cholesterol efflux.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [65] Minagawa H, Gong JS, Jung CG, et al. Mechanism underlying apolipoprotein E (ApoE) isoform‐dependent lipid efflux from neural cells in culture. J Neurosci Res. 2009; 87(11): 2498‐ 2508. doi: 10.1002/jnr.22073 19326444 PMC3065888 source
    • cites [66] Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform‐specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000; 74(3): 1008‐ 1016. doi: 10.1046/j.1471-4159.2000.0741008.x 10693931 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    In a tauopathy model, APOE4 mice exhibited the greatest lipid peroxidation, whereas APOE2 mice had the least.

    “In a tauopathy model, APOE4 mice exhibited the greatest lipid peroxidation, whereas APOE2 mice had the least.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [70] Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025; 188(1): 187‐ 206. e26. doi: 10.1016/j.cell.2024.10.027 39532095 PMC11724755 source

      The Results section ('PUFA-CE-ApoE4 promotes lipofuscin deposits in vivo'; page unavailable) reports the highest lipofuscin accumulation in APOE4 tauopathy mice. The Discussion reports an APOE4 > APOE3 > APOE2 pattern for a lipid-peroxidation product, 4-HNE, but that finding was in treated human iPSC-derived neurons, not mice. The mouse cohort listed in STAR METHODS did not include APOE2 mice, so the claimed mouse comparison is unsupported. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The Reelin pathway plays an essential role in synaptic functions.

    “The Reelin pathway plays an essential role in synaptic functions. 54”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [54] Weeber EJ, Beffert U, Jones C, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002; 277(42): 39944‐ 39952. doi: 10.1074/jbc.M205147200 12167620 source

      The Abstract reports that Reelin enhances hippocampal long-term potentiation, and the Discussion describes a role in adult hippocampal synaptic plasticity. The claim overstates this as an essential role in synaptic functions generally: the section titled “Synaptic Transmission and Short Term Plasticity Are Normal” reports normal baseline transmission and short-term plasticity in mice lacking either Reelin receptor. Page numbers are unavailable in our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Previous work using a whole-body Idol KO mouse model demonstrated an increase in brain LDLR levels with a significant decrease in Aβ accumulation.

    “Indeed, our previous work using a whole‐body Idol KO mouse model demonstrated an increase in brain LDLR levels with a significant decrease in Aβ accumulation. 20”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [20] Choi J, Gao J, Kim J, Hong C, Kim J, Tontonoz P. The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis. Sci Transl Med. 2015; 7(314): 314ra184. doi: 10.1126/scitranslmed.aad1904 PMC7153735 26582899 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    APOE2 exacerbates TDP-43 proteinopathy.

    “Similarly, APOE2 exacerbated TDP‐43 proteinopathy,”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [72] Meneses AD, Koga S, Li Z, et al. APOE2 exacerbates TDP‐43 related toxicity in the absence of Alzheimer pathology. Ann Neurol. 2023; 93(4): 830‐ 843. doi: 10.1002/ana.26580 36546684 PMC10471132 source

  • Classified as probably not a substantial claim.

    Premisecitation

    In the adult brain, Reelin signaling is important for memory and synaptic plasticity.

    “In the adult brain, Reelin signaling is important for memory and synaptic plasticity, as deletion of either Reelin (Reln) or its receptors, Vldlr and Apoer2, impairs hippocampal synaptic transmission.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [54] Weeber EJ, Beffert U, Jones C, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002; 277(42): 39944‐ 39952. doi: 10.1074/jbc.M205147200 12167620 source

      The Discussion reports that Reelin modulates hippocampal synaptic plasticity and is likely to contribute to hippocampus-dependent memory in adult mice. But the paper tested deletion of VLDlr and Apoer2, not deletion of Reelin; its section “Synaptic Transmission and Short Term Plasticity Are Normal” says baseline transmission was unaffected by either receptor deletion, although long-term potentiation was impaired. (LLM, conf=0.89)

      Experimental — accuracy not yet measured
    • cites [78] Qiu S, Korwek KM, Pratt‐Davis AR, Peters M, Bergman MY, Weeber EJ. Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice. Neurobiol Learn Mem. 2006; 85(3): 228‐ 242. doi: 10.1016/j.nlm.2005.11.001 16376115 source

  • May combine two claims.

    Premisecitation

    Reelin signaling mitigates Aβ-mediated synaptic impairment and tau phosphorylation.

    “Moreover, Reelin signaling has been demonstrated to mitigate Aβ‐mediated synaptic impairment and tau phosphorylation.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [79] Durakoglugil MS, Chen Y, White CL, Kavalali ET, Herz J. Reelin signaling antagonizes β‐amyloid at the synapse. J Proc National Academy Sciences. 2009; 106(37): 15938‐ 15943. doi: 10.1073/pnas.0908176106 PMC2747222 19805234 source

      The Results report that Reelin prevents Aβ-induced suppression of long-term potentiation, supporting the synaptic-impairment part of the claim. The paper does not report that Reelin mitigates Aβ-mediated tau phosphorylation; its phosphorylation results concern NMDA receptor subunits, while tau phosphorylation appears only in a cited reference title. (LLM, conf=0.90)

      Experimental — accuracy not yet measured
    • cites [80] Hiesberger T, Trommsdorff M, Howell BW, et al. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled‐1 and modulates tau phosphorylation. Neuron. 1999; 24(2): 481‐ 489. doi: 10.1016/s0896-6273(00)80861-2 10571241 source

      The Discussion says tau phosphorylation may be regulated by Reelin signaling, and the Figure 5 passage reports tau hyperphosphorylation in mice lacking Reelin or both of its receptors. The paper does not demonstrate that Reelin mitigates Aβ-mediated synaptic impairment, or test tau phosphorylation in an Aβ-mediated condition. (LLM, conf=0.89)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Increasing LDLR levels, either through Ldlr overexpression or by deleting its E3 ubiquitin ligase Idol, reduced APOE levels and attenuated amyloid pathology.

    “Notably, increasing LDLR levels, either through Ldlr overexpression or by deleting its E3 ubiquitin ligase Idol, reduced APOE levels and attenuated amyloid pathology.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [16] Kim J, Castellano JM, Jiang H, et al. Overexpression of low‐density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009; 64(5): 632‐ 644. doi: 10.1016/j.neuron.2009.11.013 20005821 PMC2787195 source

      The Discussion reports that LDLR overexpression in APP/PS1 mice lowered brain apoE levels and markedly reduced Aβ aggregation. Our copy does not report deleting Idol or test whether Idol deletion produced those effects (searched: Idol, E3 ubiquitin ligase, deleting Idol). (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [20] Choi J, Gao J, Kim J, Hong C, Kim J, Tontonoz P. The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis. Sci Transl Med. 2015; 7(314): 314ra184. doi: 10.1126/scitranslmed.aad1904 PMC7153735 26582899 source

  • May combine two claims.

    Premisecitation

    APOE2 mice exhibited more tau pathology compared to APOE3 and APOE4 mice, and behavioral abnormalities in a tauopathy model.

    “For example, APOE2 mice exhibited more tau pathology, compared to APOE3 and APOE4 mice, and behavioral abnormalities in a tauopathy model.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [71] Zhao N, Liu C‐C, Van Ingelgom AJ, et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nature Commun. 2018; 9(1): 4388. doi: 10.1038/s41467-018-06783-0 30348994 PMC6197187 source

  • Probably not a substantial claim: may not pass S2 (checkable).

    Premisecitation

    Enzymes are highly druggable targets.

    “enzymes are highly druggable targets,”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [85] Maciag M, Karamyan VT. The missing enzymes: a call to update pharmacological profiling practices for better drug safety assessment. J Med Chem. 2025; 68(8): 7854‐ 7865. doi: 10.1021/acs.jmedchem.4c02228 40173276 PMC12035801 source

  • May combine two claims.

    Premisecitation

    The RELN variant enhances Reelin signaling and limits tau pathology, which may underlie the observed cognitive resilience.

    “Biochemical and functional studies revealed that the RELN variant enhances Reelin signaling and limits tau pathology, which may underlie the observed cognitive resilience.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [84] Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin‐COLBOS heterozygous man. Nat Med. 2023; 29(5): 1243‐ 1252. doi: 10.1038/s41591-023-02318-3 37188781 PMC10202812 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Previous studies demonstrated that deletion of Apoe and overexpression of Ldlr can reduce tau-associated neurodegeneration.

    “previous studies have demonstrated that deletion of Apoe and overexpression of Ldlr can reduce tau‐associated neurodegeneration.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [74] Shi Y, Andhey PS, Ising C, et al. Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms. Neuron. 2021; 109(15): 2413‐ 2426. doi: 10.1016/j.neuron.2021.05.034. e7. 34157306 PMC8349883 source
    • cites [75] Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau‐mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017; 549(7673): 523‐ 527. doi: 10.1038/nature24016 28959956 PMC5641217 source

      The paper’s concluding discussion (listed under Abstract in our copy; no page given) says that absence of ApoE was strongly neuroprotective in the context of tau pathology. The passages do not report that Ldlr overexpression reduces tau-associated neurodegeneration; a search for LDLR found no relevant passage. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The individual with the RELN variant developed mild cognitive impairment approximately two decades later than the typical onset for carriers of the autosomal dominant AD mutation and exhibited relatively low tau pathology.

    “The individual developed mild cognitive impairment approximately two decades later than the typical onset for carriers of this autosomal dominant AD mutation and exhibited relatively low tau pathology.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [84] Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin‐COLBOS heterozygous man. Nat Med. 2023; 29(5): 1243‐ 1252. doi: 10.1038/s41591-023-02318-3 37188781 PMC10202812 source

      The Main section gives a median MCI onset of 44 for PSEN1-E280A carriers, and the Results case report says this individual was diagnosed at 70, supporting a substantial delay. The Results also report relatively limited tau pathology in the entorhinal cortex and some other regions, but similar tau burden in the inferior temporal lobe and extensive tau pathology at autopsy. The unqualified description of relatively low tau pathology therefore overstates the finding. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    A rare gain-of-function variant in RELN was identified in a patient with an autosomal dominant AD-causing mutation and was associated with resilience against cognitive impairment.

    “Recently, a rare gain‐of‐function variant in RELN was identified in a patient with an autosomal dominant AD‐causing mutation, and it was associated with resilience against cognitive impairment.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [84] Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin‐COLBOS heterozygous man. Nat Med. 2023; 29(5): 1243‐ 1252. doi: 10.1038/s41591-023-02318-3 37188781 PMC10202812 source

  • May combine two claims.

    Premisecitation

    Both Ldlr KO and Ldlr-Apoe double KO 5XFAD mice showed reduced astrogliosis and microgliosis, whereas Apoe KO mice did not.

    “Furthermore, both Ldlr KO and Ldlr‐Apoe double KO 5XFAD mice showed reduced astrogliosis and microgliosis, whereas Apoe KO mice did not.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [61] Katsouri L, Georgopoulos S. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. PLoS One. 2011; 6(7): e21880. doi: 10.1371/journal.pone.0021880 21755005 PMC3130747 source

  • May combine two claims.

    Findingown data

    Neuronal, but not microglial, Idol deletion reduces amyloid accumulation.

    “We demonstrated that neuronal, but not microglial, Idol deletion reduced amyloid accumulation”
    • Also stated in: § Neuronal Idol deletion decreases Aβ accumulation · plain
      “Microglial Idol deletion did not affect insoluble, guanidine‐extracted, Aβ40 or Aβ42 levels in the cortices of 5XFAD mice (Figure 1A,B). However, neuronal Idol deletion reduced insoluble Aβ40 and Aβ42 levels in the cortices of 5XFAD mice by 69% and 61%, respectively (Figure 1C,D).”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Proteomic analysis detected 11,829 proteins in the cortices of 5XFAD;Neu cKO mice.

    “We were able to detect 11,829 proteins with extensive liquid chromatography fractionation.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Translation, cell adhesion, and inflammation-related pathways were driven mainly by transcriptomic alterations, while proteolysis, cell cycle, and signal transduction pathways were primarily influenced by proteomic changes.

    “Although translation, cell adhesion, and inflammation‐related pathways were driven mainly by transcriptomic alterations, the enrichment of proteolysis, cell cycle, and signal transduction pathways was primarily influenced by proteomic changes (Figure S4B).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Unsupervised clustering identified 24 distinct clusters across the snRNA-seq samples.

    “Unsupervised clustering identified 24 distinct clusters across the samples (Figure 7A).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Proteomic pathway analysis revealed enrichment of lipid metabolism and cholesterol transport pathways, with "Cholesterol dysregulation in Alzheimer's disease" as the top pathway.

    “These analyses revealed enrichment of lipid metabolism and cholesterol transport pathways, with “Cholesterol dysregulation in Alzheimer's disease” being the top pathway (Figure 6B and Table S2).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    82E1+ amyloid plaque load and the number of plaques were decreased in the hippocampus of 5XFAD;Neu cKO mice.

    “Similarly, 82E1+ amyloid plaque load and the number of plaques were decreased in the hippocampus of 5XFAD;Neu cKO mice (Figure 2D,E).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    5XFAD;Neu cKO mice exhibited significant decreases in both the area and the number of amyloid plaques in the cortex.

    “Consistent with our biochemical analyses, we found that 5XFAD;Neu cKO mice exhibited significant decreases in both the area and the number of amyloid plaques in the cortex (Figure 2B,C).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Soluble Aβ40 and Aβ42 levels exhibited a trend of decrease but were not significantly different between genotypes in the hippocampus.

    “Soluble Aβ40 and Aβ42 levels exhibited a trend of decrease, but these changes were not significant between the genotypes (Figure S3C,D).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Soluble Aβ40 and Aβ42 levels were decreased by 34% and 45%, respectively, in the cortices of 5XFAD;Neu cKO mice.

    “Soluble Aβ40 and Aβ42 levels were also decreased by 34% and 45%, respectively, in the cortices of 5XFAD;Neu cKO mice (Figure S2A,B).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Excitatory neuron DEGs were enriched in synapse-related pathways and also in calcium-mediated signaling and G-protein signaling.

    “Excitatory neuron DEGs were similarly enriched in synapse‐related pathways but also showed enrichment in distinct pathways, such as calcium‐mediated signaling and G‐protein signaling (Figure S5C,D and Tables S11 and S12).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    CellChat analysis revealed an overall increase in cell-to-cell communication among most cell types, particularly between and within inhibitory and excitatory neurons, in 5XFAD;Neu cKO mice.

    “These analyses revealed an overall increase in cell‐to‐cell communication among most cell types, particularly between and within inhibitory and excitatory neurons in 5XFAD;Neu cKO mice (Figure 8A,B).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Neuronal, not microglial, IDOL plays a key role in regulating brain APOE and LDLR levels, as well as Aβ accumulation.

    “Here, we demonstrate that neuronal, not microglial, IDOL plays a key role in regulating brain APOE and LDLR levels, as well as Aβ accumulation.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Neuronal IDOL, but not microglial IDOL, plays a key role in Alzheimer's disease pathogenesis by regulating the levels of brain APOE receptors.

    “Neuronal IDOL, but not microglial IDOL, plays a key role in Alzheimer's disease pathogenesis by regulating the levels of brain APOE receptors.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    Increasing brain LDLR levels could reduce APOE and Aβ, offering a potential therapeutic strategy for Alzheimer's disease.

    “These findings suggest that increasing brain LDLR levels could reduce APOE and Aβ, offering a potential therapeutic strategy for AD.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Premisereasoning

    The cell type-specific mechanisms underlying amyloid reduction by Idol deletion remained unknown.

    “However, because this approach targeted all cell types in every tissue, the cell type–specific mechanisms underlying amyloid reduction remained unknown.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    The researchers were blinded during the quantification of histology samples.

    “The researchers were blinded during the quantification of histology samples.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Sample sizes were determined based on statistical power calculations, aiming to generate 12 mice per genotype using a standard deviation of 150, an effect size of 60% for insoluble Aβ42 levels, a power of 0.8, and p < 0.05.

    “Using a standard deviation (SD) of 150, an effect size of 60% for insoluble Aβ42 levels, a power of 0.8, and p < 0.05, we aimed to generate 12 mice per genotype.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based).

    Study design and conductnone given

    The age of 4 months is when pathological changes can be reliably detected and expected beneficial effects observed without overwhelming pathology.

    “We collected the brain tissues from 5XFAD;MG cKO, neuronal Idol KO 5XFAD mice (referred to as 5XFAD;Neu cKO), and 5XFAD littermate controls at 4 months of age, the age that we can reliably detect pathological changes as well as observe the expected beneficial effects without overwhelming pathology.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationown data

    The LDLR-APOE axis plays a critical role in Aβ accumulation and is regulated by neuronal IDOL.

    “These results highlight the critical role of the LDLR‐APOE axis in Aβ accumulation and its regulation by neuronal IDOL.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    Neuronal IDOL plays an important role in Aβ accumulation, gliosis, and the regulation of inhibitory neurons involved in synaptic organization via LDLR and Reelin receptors.

    “Our findings indicate that the neuronal IDOL plays an important role in Aβ accumulation, gliosis, and the regulation of inhibitory neurons involved in synaptic organization via LDLR and Reelin receptors.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    The order of animals was randomized for each experiment.

    “The order of animals was randomized for each experiment.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    Prior research establishes that increasing APOE receptors mitigates Alzheimer's disease pathology.

    “Prior research establishes that increasing APOE receptors mitigates AD pathology.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Changes in LDLR level may alter cellular lipid content and contribute to reduced Aβ levels in 5XFAD;Neu cKO mice.

    “Because LDLR mediates the uptake of APOE‐bound lipid particles and Aβ, changes in the LDLR level may alter the cellular lipid content and contribute to the reduced Aβ levels in 5XFAD;Neu cKO mice.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: LDLR mediates the uptake of APOE-bound lipid particles and Aβ.

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    Direct pharmacological upregulation of APOE receptors remains challenging.

    “However, direct pharmacological upregulation of these proteins remains challenging.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationown data

    Neuronal IDOL may contribute to AD not only by affecting Aβ accumulation but also by modulating synaptic functions.

    “These findings suggest that neuronal IDOL may contribute to AD, not only by affecting Aβ accumulation but also by modulating synaptic functions.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    Neuronal IDOL regulates lipid metabolism and protein accumulation in AD.

    “These findings further strengthen the role of neuronal IDOL in regulating lipid metabolism and protein accumulation in AD.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationown data

    Differences between transcriptomic and proteomic datasets may reflect post-transcriptional regulatory mechanisms.

    “These differences between transcriptomic and proteomic datasets may reflect post‐transcriptional regulatory mechanisms.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Gliosis is another pathological hallmark of AD, emerging at very early stages of the disease.

    “Gliosis is another pathological hallmark of AD, emerging at very early stages of the disease. 50 , 51”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [50] Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021; 17(3): 157‐ 172. doi: 10.1038/s41582-020-00435-y 33318676 source
    • cites [51] Wyss‐Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12(9): 1005‐ 1015. doi: 10.1038/nm1484 16960575

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD.

    “Notably, deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD. 3 , 4”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [3] Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta‐peptide deposition. Nat Genet. 1997; 17(3): 263‐ 264. doi: 10.1038/ng1197-263 9354781 source
    • cites [4] Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999; 96(26): 15233‐ 15238. doi: 10.1073/pnas.96.26.15233 10611368 PMC24803 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Amyloid plaque formation is typically accompanied by gliosis.

    “Although the causal link between Aβ accumulation and gliosis remains unclear, amyloid plaque formation is typically accompanied by gliosis.”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [50] Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021; 17(3): 157‐ 172. doi: 10.1038/s41582-020-00435-y 33318676 source
    • cites [51] Wyss‐Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12(9): 1005‐ 1015. doi: 10.1038/nm1484 16960575

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [52] Liddelow SA, Marsh SE, Stevens B. Microglia and astrocytes in disease: dynamic duo or partners in crime?. Trends Immunol. 2020; 41(9): 820‐ 835. doi: 10.1016/j.it.2020.07.006 32819809 source

  • May combine two claims.

    Interpretationown data

    Neuronal Idol deletion enhances cellular interactions, except in microglia and oligodendrocytes.

    “Collectively, these findings suggest that neuronal Idol deletion enhances cellular interactions, except in microglia and oligodendrocytes.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    snRNA-seq analysis was performed on a modest sample size (N = 2 mice/genotype).

    “Even though snRNA‐seq analysis was performed on a modest sample size (N = 2 mice/genotype), given the high yield of our single nuclei isolation protocol, we were able to detect transcriptomic changes across multiple cell types.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Neurexins are presynaptic adhesion molecules critical for synaptic transmission.

    “Neurexins, presynaptic adhesion molecules, are critical for synaptic transmission. 55”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [55] Dean C, Scholl FG, Choih J, et al. Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci. 2003; 6(7): 708‐ 716. doi: 10.1038/nn1074 12796785 PMC1646425 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    We did not assess the effect of Idol deletion on tauopathy.

    “Although we did not assess the effect of Idol deletion on tauopathy,”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    IDOL inhibition may be a viable approach for AD, as it regulates LDLR-mediated APOE uptake.

    “Therefore, IDOL inhibition may be a viable approach, as it regulates LDLR‐mediated APOE uptake.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Findings from mouse models of AD, including 5XFAD;Neu cKO mice, are predictive of human AD.
    • Rests on an assumption: Pharmacological inhibition of IDOL in humans is feasible and safe.

  • May combine two claims.

    Study design and conductnone given

    The Camk2a-Cre mouse model initiates Cre-loxP recombination postnatally, not during the embryonic stage, avoiding potential developmental defects or compensatory responses.

    “Because we used the Camk2a‐Cre mouse model that initiates Cre‐loxP recombination postnatally, not during the embryonic stage, any potential developmental defects or compensatory responses were avoided.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    VLDLR and APOER2 mediate Reelin signaling, which is essential for neuronal migration during brain development.

    “VLDLR and APOER2 mediate Reelin signaling, which is essential for neuronal migration during brain development.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [77] Trommsdorff M, Gotthardt M, Hiesberger T, et al. Reeler/Disabled‐like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999; 97(6): 689‐ 701. doi: 10.1016/s0092-8674(00)80782-5 10380922 source

  • May combine two claims.

    Interpretationreasoning

    Targeting neuronal IDOL may offer multiple therapeutic benefits in AD by simultaneously reducing amyloid burden and gliosis while enhancing synaptic health.

    “Thus, targeting neuronal IDOL may offer multiple therapeutic benefits in AD by simultaneously reducing amyloid burden and gliosis while enhancing synaptic health.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Findings from mouse models of AD, including 5XFAD;Neu cKO mice, are predictive of human AD.
    • Rests on an assumption: Pharmacological inhibition of IDOL in humans is feasible and safe.

  • May combine two claims.

    Interpretationreasoning

    The beneficial effects observed in 5XFAD;Neu cKO mice may be due to decreased APOE levels, but this is likely not the only mechanism.

    “Although the beneficial effects observed in 5XFAD;Neu cKO mice may be due to decreased APOE levels (Figure 4C), this is likely not the only mechanism.”
    Quote in the paperNot a substantial claim
71 of 71

  • The paper relies on this without support.

    IDOL targets LDLR for degradation.

    “Since IDOL targets LDLR for its degradation, we assessed LDLR levels in the brains of 5XFAD;MG cKO and 5XFAD;Neu cKO mice using Western blot analysis (Figure 4).”

  • The paper relies on this without support.

    IDOL is expressed primarily in microglia and neurons in the brain.

    “Because Idol is expressed primarily in microglia and neurons in the brain, we examined its role in these cell types and its contribution to amyloid pathology.”

  • The paper relies on this without support.

    Bulk RNA-seq lacks cell-type specificity.

    “Bulk RNA‐seq provides useful insights; however, it lacks cell‐type specificity.”

  • The paper relies on this without support.

    LDLR mediates the uptake of APOE-bound lipid particles and Aβ.

    “Because LDLR mediates the uptake of APOE‐bound lipid particles and Aβ, changes in the LDLR level may alter the cellular lipid content and contribute to the reduced Aβ levels in 5XFAD;Neu cKO mice.”

  • The paper relies on this without support.

    Findings from mouse models of AD, including 5XFAD;Neu cKO mice, are predictive of human AD.

    “Thus, targeting neuronal IDOL may offer multiple therapeutic benefits in AD by simultaneously reducing amyloid burden and gliosis while enhancing synaptic health.”

  • The paper relies on this without support.

    Pharmacological inhibition of IDOL in humans is feasible and safe.

    “Given that IDOL is an E3 ubiquitin ligase and enzymes are highly druggable targets, 85 its pharmacological inhibition represents a promising strategy for AD treatment.”
6 of 6

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

This check didn’t finish.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. 10.1016/S0092‐8674(00)81826‐73B;pii3D; · DOI

Cited by

Sorted by citations

Authors
Karahan, H., Hartigan, K., Al‐Amin, M. M., John, S. K., McCord, B., Wijeratne, H. R. S., Acri, D. J., Smith, D. C., Dabin, L. C., Cordero, H. M. R., Kim, B., Lee, D., & Kim, J.
Affiliations
  • Indiana University Indianapolis (US)
  • Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis Indiana USA
Corresponding author
Kim, Jungsu
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2025-12
Volume
21
Issue
12
Pages
e70949-e70949
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.70949
PMC
PMC12699379
OpenAlex
W4417274554
Semantic Scholar
4ac670aaa307969bd23a5221b38b943af37b89c3
Cited by
2
References
52
Citations by year
2026: 2
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
Funders
  • National Institute on Aging (R01AG053242)
  • Alzheimer's Association (NIRG‐12‐240682)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
Alzheimer's disease, idols
MeSH terms
Reelin Protein, Alzheimer Disease, Animals, Apolipoproteins E, Brain, Disease Models, Animal, Neurons, Receptors, LDL, Amyloid beta-Peptides, Microglia, Mice, Knockout, Ubiquitin-Protein Ligases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-17.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-17.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review